GeneOne Life Science, Inc. Statistics
Want to see KR:011000 full AI Analyst Report?
GeneOne Life Science, Inc. (011000) Stock Statistics & Valuation Metrics
Total Valuation
GeneOne Life Science, Inc. has a market cap or net worth of KRW 48.51B. The enterprise value is KRW 76.53B.
- Market Cap
- KRW 48.51B
- Enterprise Value
- KRW 76.53B
Share Statistics
GeneOne Life Science, Inc. has 18,176,582 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 18,176,582
- Owned by Insiders
- ―
- Owned by Institutions
- 12.87%
Financial Efficiency
GeneOne Life Science, Inc.’s return on equity (ROE) is -1.17 and return on invested capital (ROIC) is -55.99%.
- Return on Equity (ROE)
- -1.17
- Return on Assets (ROA)
- -0.40
- Return on Invested Capital (ROIC)
- -55.99%
- Return on Capital Employed (ROCE)
- -0.65
- Revenue Per Employee
- 520.24M
- Profits Per Employee
- -1.04B
- Employee Count
- 46
- Asset Turnover
- 0.20
- Inventory Turnover
- 3.38
Valuation Ratios
The current PE Ratio of GeneOne Life Science, Inc. is -0.23. GeneOne Life Science, Inc.’s PEG ratio is -0.01.
- PE Ratio
- -0.23
- PS Ratio
- 2.69
- PB Ratio
- 0.91
- Price to FCF
- -3.04
- Price to Operating Cash Flow
- -2.92
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, GeneOne Life Science, Inc. had revenue of 23.93B and earned -47.66B in profits. Earnings per share was -13951.00.
- Revenue
- 23.93B
- Gross Profit
- -21.43B
- Operating Income
- -42.42B
- Pretax Income
- -47.57B
- Net Income
- -47.66B
- EBITDA
- -28.60B
- Earnings Per Share (EPS)
- -13951.00
Cash Flow
In the last 12 months, operating cash flow was -15.88B and capital expenditures -34.44M, giving a free cash flow of -15.91B billion.
- Operating Cash Flow
- -15.88B
- Free Cash Flow
- -15.91B
- Free Cash Flow per Share
- -916.23
Dividends & Yields
GeneOne Life Science, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32.87%
- Earnings Yield
- -88.86%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- -76.78%
- 50-Day Moving Average
- 2670.00
- 200-Day Moving Average
- 4002.43
- Relative Strength Index (RSI)
- 27.53
- Average Volume (3m)
- ―
Important Dates
GeneOne Life Science, Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
GeneOne Life Science, Inc. as a current ratio of 0.36, with Debt / Equity ratio of 80.58%
- Current Ratio
- 0.36
- Quick Ratio
- 0.11
- Debt to Market Cap
- 0.87
- Net Debt to EBITDA
- -1.11
- Interest Coverage Ratio
- -17.87
Taxes
In the past 12 months, GeneOne Life Science, Inc. has paid 87.41M in taxes.
- Income Tax
- 87.41M
- Effective Tax Rate
- -0.00
Enterprise Valuation
GeneOne Life Science, Inc. EV to EBITDA ratio is -2.94, with an EV/FCF ratio of -4.86.
- EV to Sales
- 4.29
- EV to EBITDA
- -2.94
- EV to Free Cash Flow
- -4.86
- EV to Operating Cash Flow
- -4.87
Balance Sheet
GeneOne Life Science, Inc. has KRW 6.82B in cash and marketable securities with KRW 34.15B in debt, giving a net cash position of -KRW 27.33B billion.
- Cash & Marketable Securities
- KRW 6.82B
- Total Debt
- KRW 34.15B
- Net Cash
- -KRW 27.33B
- Net Cash Per Share
- -KRW 1,503.52
- Tangible Book Value Per Share
- KRW 2,932.71
Margins
Gross margin is -79.36%, with operating margin of -198.24%, and net profit margin of -228.82%.
- Gross Margin
- -79.36%
- Operating Margin
- -198.24%
- Pretax Margin
- -228.46%
- Net Profit Margin
- -228.82%
- EBITDA Margin
- -145.76%
- EBIT Margin
- -222.53%
Analyst Forecast
The average price target for GeneOne Life Science, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -64.38%
- EPS Growth Forecast
- 10.38%
Scores
- Smart Score
- ―
- AI Score
- 41

